Navigation Links
iCardiac Selected for Multiple Cardiac Safety Studies
Date:6/15/2009

Continues Market Leadership in Highly Automated QT(sm) Evaluation and Helps Sponsors Avoid False Positives

Rochester, NY (PRWEB) June 15, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that it has been chosen by a medium sized pharmaceutical company for cardiac safety evaluation comprising multiple Thorough QT (TQT) Studies.

iCardiac will use its FDA accepted Highly Automated QT method for all contracted studies in addition to using iCardiac's QTbtb(sm) method for avoiding false positives. The sponsor selected iCardiac because of both iCardiac's cardiac safety expertise in relation to complex drug development programs as well as the extensive validation of iCardiac's COMPAS technology. COMPAS Highly Automated QT leads the industry in validation and deployments covering over 1.5 million ECGs analyzed with partners including pharmaceutical companies, academia, regulators, as well as having been cross validated with result from five leading ECG core labs.

"We are enthusiastic about the markets continued acceptance of iCardiac's Highly Automated QT solution," said Sasha Latypova, Executive Vice President. "In addition to increasing the robustness of cardiac safety evaluation and reducing the likelihood of false positives through the use of iCardiac's proprietary QTbtb method, the sponsor will realize increased economic efficiencies in comparison to traditional QT studies."

About iCardiac Technologies:
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/tqt/cardiacsafety/prweb2526064.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Reports Significant Revenue Growth and Profitability
2. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
3. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
4. Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner
5. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
6. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
7. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Solazyme Selected for National Institute of Standards and Technology Award
10. Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America
11. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation ... Physics and Astronomy, has been selected for membership in ARCS Alumni Hall of ... Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of the ...
(Date:10/9/2017)... Texas (PRWEB) , ... October ... ... study published on October 5, 2017, in the medical journal, Epilepsia, Brain ... with the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):